agilon health, inc. (AGL) stock
Close on Nov 17, 2026Market cap $1.93BP/E –Yield –
Earnings
agilon health's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of agilon health's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 24, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $1.52B | +5.6% | $1.97 | – | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026during market hours | $1.49B | +7.2% | – | $70.00 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026during market hours | – | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026during market hours | $1.57B | +3.3% | -$0.46 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025during market hours | $1.44B | -0.7% | -$0.27 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025during market hours | $1.39B | -6.1% | -$0.25 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025during market hours | $1.53B | -4.4% | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 25, 2025during market hours | $1.52B | +43.4% | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024during market hours | $1.45B | +18.9% | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024during market hours | $1.48B | +28.7% | -$0.07 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $1.60B | +40.4% | $0.01 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024during market hours | $1.06B | +53.6% | -$0.41 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023during market hours | $1.22B | +75.5% | -$0.08 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | $1.15B | +71.6% | -$0.04 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $1.14B | +74.6% | $0.04 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023during market hours | $690.00M | +49.0% | -$0.14 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $695.00M | +51.4% | -$0.07 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $670.00M | – | -$0.05 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022during market hours | $653.00M | – | – | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022during market hours | $463.00M | – | -$0.14 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021during market hours | $459.00M | – | -$0.09 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 26, 2021during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
agilon health's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total RevenuesGAAP | FY2026 | $5.87B – $5.89B | – | New | Nov 4, 2026 |
| Total Revenues | FY2026 | $5.41B – $5.58B | – | New | Feb 25, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $145.00M – $155.00M | – | New | Nov 4, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | -$15.00M – $15.00M | – | New | Feb 25, 2026 |
| ACO Model Members | FY2026 | 108,000 – 112,000 | – | Lowered | Nov 4, 2026 |
| ACO Model Members | FY2026 | 100,000 – 105,000 | – | Lowered | Feb 25, 2026 |
| Avg. Medicare Advantage Members | FY2026 | 451,000 – 453,000 | – | Lowered | Nov 4, 2026 |
| Avg. Medicare Advantage Members | FY2026 | 427,000 – 437,000 | – | Lowered | Feb 25, 2026 |
| Geography Entry Costs | FY2026 | $15.00M | – | New | Nov 4, 2026 |
| Geography Entry Costs | FY2026 | $15.00M | – | New | Feb 25, 2026 |
| Medical Marginnon-GAAP | FY2026 | $300.00M – $350.00M | – | New | Feb 25, 2026 |
| Medicare Advantage Members | FY2026 | 445,000 – 450,000 | – | New | Nov 4, 2026 |
| Medicare Advantage Members | FY2026 | 425,000 – 435,000 | – | New | Feb 25, 2026 |
| MSER | FY2026 | 90.3% – 90.5% | – | New | Nov 4, 2026 |
| Selling, general and administrative expenses | FY2026 | $234.00M | – | Raised | Feb 25, 2026 |
| Total Members Live on Platform | FY2026 | 553,000 – 562,000 | – | Raised | Nov 4, 2026 |
| Total Members Live on Platform | FY2026 | 525,000 – 540,000 | – | Raised | Feb 25, 2026 |
Guidance vs results
The last range agilon health gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $5.81B – $5.83B | $5.93BΣ4Q | Above range |
| Q2 FY2025 | Revenue | $1.44B – $1.51B | $1.39B | Below range |
| Q1 FY2025 | Revenue | $1.48B – $1.52B | $1.53B | Above range |
| Q3 FY2024 | Revenue | $1.47B – $1.48B | $1.45B | Below range |
| Q2 FY2024 | Revenue | $1.55B – $1.57B | $1.48B | Below range |
| Q1 FY2024 | Revenue | $1.61B – $1.63B | $1.60B | Below range |
| Q4 FY2023 | Revenue | $1.05B – $1.06B | $1.06B | Within range |
| Q3 FY2023 | Revenue | $1.13B – $1.14B | $1.22B | Above range |
| Q2 FY2023 | Revenue | $1.11B – $1.12B | $1.15B | Above range |
| Q1 FY2023 | Revenue | $1.07B – $1.09B | $1.14B | Above range |
| Q3 FY2022 | Revenue | $645.00M – $655.00M | $695.00M | Above range |
| Q2 FY2022 | Revenue | $640.00M – $652.00M | $670.00M | Above range |
| Q1 FY2022 | Revenue | $635.00M – $650.00M | $653.00M | Above range |
Guidance history
Every forecast agilon health put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted EBITDA | FY2026 | $145.00M – $155.00M | New |
| Nov 4, 2026 | MSER | FY2026 | 90.3% – 90.5% | New |
| Nov 4, 2026 | Avg. Medicare Advantage Members | FY2026 | 451,000 – 453,000 | Lowered |
| Nov 4, 2026 | Total Members Live on Platform | FY2026 | 553,000 – 562,000 | Raised |
| Nov 4, 2026 | ACO Model Members | FY2026 | 108,000 – 112,000 | Lowered |
| Nov 4, 2026 | Medicare Advantage Members | FY2026 | 445,000 – 450,000 | New |
| Nov 4, 2026 | Geography Entry Costs | FY2026 | $15.00M | New |
| Nov 4, 2026 | Total Revenues | FY2026 | $5.87B – $5.89B | New |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | -$15.00M – $15.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | Q1 FY2026 | $35.00M – $45.00M | New |
| Feb 25, 2026 | Total Members Live on Platform | FY2026 | 525,000 – 540,000 | Raised |
| Feb 25, 2026 | Medical Margin | Q1 FY2026 | $115.00M – $130.00M | New |
| Feb 25, 2026 | Geography Entry Costs | Q1 FY2026 | $3.00M | New |
| Feb 25, 2026 | Medicare Advantage Members | FY2026 | 425,000 – 435,000 | New |
| Feb 25, 2026 | ACO Model Members | FY2026 | 100,000 – 105,000 | Lowered |
| Feb 25, 2026 | Avg. Medicare Advantage Members | FY2026 | 427,000 – 437,000 | Lowered |
| Feb 25, 2026 | Geography Entry Costs | FY2026 | $15.00M | New |
| Feb 25, 2026 | Selling, general and administrative expenses | FY2026 | $234.00M | Raised |
| Feb 25, 2026 | Medical Margin | FY2026 | $300.00M – $350.00M | New |
| Feb 25, 2026 | Medicare Advantage Members | Q1 FY2026 | 431,000 – 441,000 | New |
| Feb 25, 2026 | ACO Model Members | Q1 FY2026 | 105,000 – 110,000 | Lowered |
| Feb 25, 2026 | Total Members Live on Platform | Q1 FY2026 | 536,000 – 551,000 | Raised |
| Feb 25, 2026 | Avg. Medicare Advantage Members | Q1 FY2026 | 430,000 – 440,000 | Lowered |
| Feb 25, 2026 | Total Revenues | FY2026 | $5.41B – $5.58B | New |
| Feb 25, 2026 | Total Revenues | Q1 FY2026 | $1.35B – $1.39B | New |
| Nov 4, 2025 | Adjusted EBITDA | FY2025 | -$270.00M – -$245.00M | New |
| Nov 4, 2025 | Medical Margin | FY2025 | -$5.00M – $15.00M | New |
| Nov 4, 2025 | Medicare Advantage Members | FY2025 | 503,000 – 506,000 | New |
| Nov 4, 2025 | ACO Model Members | FY2025 | 113,000 – 115,000 | Lowered |
| Nov 4, 2025 | Total Members Live on Platform | FY2025 | 616,000 – 621,000 | Raised |
| Nov 4, 2025 | Avg. Medicare Advantage Members | FY2025 | 500,000 – 501,000 | Lowered |
| Nov 4, 2025 | Geography Entry Costs | FY2025 | $32.00M – $30.00M | New |
| Nov 4, 2025 | Total Revenues | FY2025 | $5.81B – $5.83B | New |
| May 6, 2025 | Adjusted EBITDA contribution from ACO model | FY2025 | $35.00M – $40.00M | Raised |
| May 6, 2025 | Adjusted EBITDA | Q2 FY2025 | -$35.00M – -$20.00M | New |
| May 6, 2025 | ACO Model Members | Q2 FY2025 | 105,000 – 115,000 | Lowered |
| May 6, 2025 | Total Members Live on Platform | Q2 FY2025 | 590,000 – 630,000 | Raised |
| May 6, 2025 | Avg. Medicare Advantage Members | Q2 FY2025 | 494,000 – 532,000 | Lowered |
| May 6, 2025 | Medical Margin | Q2 FY2025 | $50.00M – $70.00M | New |
| May 6, 2025 | Geography Entry Costs | Q2 FY2025 | $11.00M – $10.00M | Lowered |
| May 6, 2025 | ACO Model Members | FY2025 | 105,000 – 115,000 | New |
| May 6, 2025 | Geographic entry costs | FY2025 | $35.00M – $40.00M | Lowered |
| May 6, 2025 | Medicare Advantage Members | Q2 FY2025 | 485,000 – 515,000 | New |
| May 6, 2025 | Total Revenues | Q2 FY2025 | $1.44B – $1.51B | New |
| Feb 25, 2025 | Adjusted EBITDA | FY2025 | -$95.00M – -$55.00M | New |
| Feb 25, 2025 | Adjusted EBITDA | Q1 FY2025 | $10.00M – $25.00M | New |
| Feb 25, 2025 | Total Members Live on Platform | Q1 FY2025 | 595,000 – 625,000 | Raised |
| Feb 25, 2025 | Medicare Advantage Members | Q1 FY2025 | 490,000 – 510,000 | New |
| Feb 25, 2025 | ACO Model Members | Q1 FY2025 | 105,000 – 115,000 | Lowered |
| Feb 25, 2025 | Avg. Medicare Advantage Members | Q1 FY2025 | 490,000 – 510,000 | Lowered |
| Feb 25, 2025 | Geography Entry Costs | Q1 FY2025 | $10.00M – $9.00M | New |
| Feb 25, 2025 | Medical Margin | Q1 FY2025 | $125.00M – $140.00M | New |
| Feb 25, 2025 | Medicare Advantage Members | FY2025 | 490,000 – 520,000 | New |
| Feb 25, 2025 | ACO Model Members | FY2025 | 105,000 – 115,000 | Lowered |
| Feb 25, 2025 | Total Members Live on Platform | FY2025 | 595,000 – 635,000 | Raised |
| Feb 25, 2025 | Avg. Medicare Advantage Members | FY2025 | 489,000 – 516,000 | Lowered |
| Feb 25, 2025 | Geography Entry Costs | FY2025 | $40.00M – $35.00M | Lowered |
| Feb 25, 2025 | Medical Margin | FY2025 | $275.00M – $325.00M | New |
| Feb 25, 2025 | Total Revenues | FY2025 | $5.83B – $6.03B | New |
| Feb 25, 2025 | Total Revenues | Q1 FY2025 | $1.48B – $1.52B | New |
| Aug 6, 2024 | Adjusted EBITDA | FY2024 | -$60.00M – -$15.00M | Reaffirmed |
| Aug 6, 2024 | Adjusted EBITDA contribution from ACO model | FY2024 | $35.00M | Raised |
| Aug 6, 2024 | Adjusted EBITDA | Q3 FY2024 | -$30.00M – -$10.00M | New |
| Aug 6, 2024 | Adjusted EBITDA contribution from ACO model | Q3 FY2024 | $8.00M | Raised |
| Aug 6, 2024 | Medical Margin | FY2024 | $400.00M – $450.00M | Raised |
| Aug 6, 2024 | Total Members Live on Platform | FY2024 | 641,000 – 648,000 | Raised |
| Aug 6, 2024 | Medicare Advantage Members | Q3 FY2024 | 514,000 – 516,000 | New |
| Aug 6, 2024 | Avg. Medicare Advantage Members | FY2024 | 513,000 – 514,000 | Lowered |
| Aug 6, 2024 | Geography Entry Costs | FY2024 | $45.00M – $55.00M | Lowered |
| Aug 6, 2024 | ACO Model Members | Q3 FY2024 | 125,000 – 130,000 | Lowered |
| Aug 6, 2024 | Total Members Live on Platform | Q3 FY2024 | 639,000 – 646,000 | Raised |
| Aug 6, 2024 | Avg. Medicare Advantage Members | Q3 FY2024 | 511,000 – 513,000 | Lowered |
| Aug 6, 2024 | Medical Margin | Q3 FY2024 | $90.00M – $110.00M | New |
| Aug 6, 2024 | Geography Entry Costs | Q3 FY2024 | $14.00M – $19.00M | Lowered |
| Aug 6, 2024 | Medicare Advantage Members | FY2024 | 518,000 – 520,000 | Raised |
| Aug 6, 2024 | ACO Model Members | FY2024 | 123,000 – 128,000 | Lowered |
| Aug 6, 2024 | Total Revenues | FY2024 | $6.01B – $6.04B | Lowered |
| Aug 6, 2024 | Total Revenues | Q3 FY2024 | $1.47B – $1.48B | New |
| May 7, 2024 | Adjusted EBITDA | Q2 FY2024 | -$15.00M – $0 | New |
| May 7, 2024 | Adjusted EBITDA | FY2024 | -$60.00M – -$15.00M | Lowered |
| May 7, 2024 | Geography Entry Costs | FY2024 | $55.00M – $65.00M | Lowered |
| May 7, 2024 | Avg. Medicare Advantage Members | FY2024 | 510,000 – 514,000 | Lowered |
| May 7, 2024 | Medical Margin | FY2024 | $400.00M – $450.00M | Reaffirmed |
| May 7, 2024 | Medicare Advantage Members | Q2 FY2024 | 513,000 – 518,000 | New |
| May 7, 2024 | ACO Model Members | Q2 FY2024 | 123,000 – 128,000 | Lowered |
| May 7, 2024 | Total Members Live on Platform | Q2 FY2024 | 636,000 – 646,000 | Raised |
| May 7, 2024 | Avg. Medicare Advantage Members | Q2 FY2024 | 514,000 – 519,000 | Lowered |
| May 7, 2024 | Medical Margin | Q2 FY2024 | $100.00M – $120.00M | New |
| May 7, 2024 | Geography Entry Costs | Q2 FY2024 | $16.00M – $18.00M | Lowered |
| May 7, 2024 | Medicare Advantage Members | FY2024 | 510,000 – 515,000 | Lowered |
| May 7, 2024 | ACO Model Members | FY2024 | 120,000 – 125,000 | Lowered |
| May 7, 2024 | Total Members Live on Platform | FY2024 | 630,000 – 640,000 | Raised |
| May 7, 2024 | Total Revenues | Q2 FY2024 | $1.55B – $1.57B | New |
| May 7, 2024 | Total Revenues | FY2024 | $6.13B – $6.18B | Lowered |
| Feb 27, 2024 | Adjusted EBITDA | Q1 FY2024 | $15.00M – $25.00M | New |
| Feb 27, 2024 | Adjusted EBITDA contribution from ACO REACH | Q1 FY2024 | $14.00M | Lowered |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | -$60.00M – -$15.00M | New |
| Feb 27, 2024 | Adjusted EBITDA contribution from ACO REACH | FY2024 | $40.00M | Raised |
| Feb 27, 2024 | Geography Entry Costs | FY2024 | $55.00M – $65.00M | New |
| Feb 27, 2024 | geographic entry costs | FY2025 | $55.00M – $65.00M | New |
| Feb 27, 2024 | Medicare Advantage Members | Q1 FY2024 | 520,000 – 530,000 | New |
| Feb 27, 2024 | ACO REACH Members | Q1 FY2024 | 125,000 – 130,000 | Lowered |
| Feb 27, 2024 | Total Members Live on Platform | Q1 FY2024 | 645,000 – 660,000 | Raised |
| Feb 27, 2024 | Avg. Medicare Advantage Members | Q1 FY2024 | 516,000 – 525,000 | Lowered |
| Feb 27, 2024 | Geography Entry Costs | Q1 FY2024 | $20.00M – $23.00M | New |
| Feb 27, 2024 | Medical Margin | Q1 FY2024 | $155.00M – $170.00M | New |
| Feb 27, 2024 | Medicare Advantage Members | FY2024 | 540,000 – 550,000 | New |
| Feb 27, 2024 | ACO REACH Members | FY2024 | 120,000 – 125,000 | Lowered |
| Feb 27, 2024 | Total Members Live on Platform | FY2024 | 660,000 – 675,000 | Raised |
| Feb 27, 2024 | Avg. Medicare Advantage Members | FY2024 | 527,000 – 536,000 | Lowered |
| Feb 27, 2024 | medical cost trend | FY2024 | 6.6% | New |
| Feb 27, 2024 | Medical Margin | FY2024 | $400.00M – $450.00M | New |
| Feb 27, 2024 | Total Revenues | FY2024 | $6.35B – $6.47B | New |
| Feb 27, 2024 | Total Revenues | Q1 FY2024 | $1.61B – $1.63B | New |
| Nov 2, 2023 | Adjusted EBITDA | FY2023 | $6.00M – $18.00M | Lowered |
| Nov 2, 2023 | Adjusted EBITDA contribution from ACO REACH | FY2023 | $39.00M | Raised |
| Nov 2, 2023 | Adjusted EBITDA | Q4 FY2023 | -$36.00M – -$24.00M | New |
| Nov 2, 2023 | Adjusted EBITDA contribution from ACO REACH | Q4 FY2023 | $6.00M | Raised |
| Nov 2, 2023 | Total Members Live on Platform | Q4 FY2023 | 469,000 – 476,000 | Raised |
| Nov 2, 2023 | Avg. Medicare Advantage (MA) Members | Q4 FY2023 | 383,000 – 385,000 | Lowered |
| Nov 2, 2023 | Medical Margin | Q4 FY2023 | $55.00M – $70.00M | New |
| Nov 2, 2023 | Geography Entry Costs | Q4 FY2023 | $20.00M – $18.00M | Lowered |
| Nov 2, 2023 | Medicare Advantage (MA) Members | FY2023 | 384,000 – 386,000 | New |
| Nov 2, 2023 | ACO REACH Members | FY2023 | 85,000 – 90,000 | Lowered |
| Nov 2, 2023 | Total Members Live on Platform | FY2023 | 469,000 – 476,000 | Raised |
| Nov 2, 2023 | Medical Margin | FY2023 | $455.00M – $470.00M | Lowered |
| Nov 2, 2023 | Avg. Medicare Advantage (MA) Members | FY2023 | 377,000 – 378,000 | Lowered |
| Nov 2, 2023 | Geography Entry Costs | FY2023 | $69.00M – $67.00M | Lowered |
| Nov 2, 2023 | Medicare Advantage (MA) Members | Q4 FY2023 | 384,000 – 386,000 | New |
| Nov 2, 2023 | ACO REACH Members | Q4 FY2023 | 85,000 – 90,000 | Lowered |
| Nov 2, 2023 | Total Revenues | FY2023 | $4.31B – $4.32B | New |
| Nov 2, 2023 | Total Revenues | Q4 FY2023 | $1.05B – $1.06B | New |
| Aug 3, 2023 | Adjusted EBITDA ($M) | FY2023 | $0 – $23.00M | Narrowed |
| Aug 3, 2023 | Adjusted EBITDA contribution from ACO REACH | FY2023 | $30.00M – $35.00M | Raised |
| Aug 3, 2023 | Adjusted EBITDA ($M) | Q3 FY2023 | -$8.00M – $0 | New |
| Aug 3, 2023 | Medical Margin ($M) | FY2023 | $500.00M – $530.00M | Raised |
| Aug 3, 2023 | Avg. Medicare Advantage Members | FY2023 | 409,000 – 410,000 | Lowered |
| Aug 3, 2023 | Geography Entry Costs ($M) | FY2023 | $68.00M – $75.00M | Narrowed |
| Aug 3, 2023 | Medicare Advantage Members | Q3 FY2023 | 410,000 – 413,000 | New |
| Aug 3, 2023 | ACO REACH Members | Q3 FY2023 | 85,000 – 90,000 | Lowered |
| Aug 3, 2023 | Total Members Live on Platform | Q3 FY2023 | 495,000 – 503,000 | Raised |
| Aug 3, 2023 | Avg. Medicare Advantage Members | Q3 FY2023 | 413,000 – 416,000 | Lowered |
| Aug 3, 2023 | Geography Entry Costs ($M) | Q3 FY2023 | $20.00M – $22.00M | New |
| Aug 3, 2023 | Medical Margin ($M) | Q3 FY2023 | $110.00M – $125.00M | New |
| Aug 3, 2023 | Medicare Advantage Members | FY2023 | 412,000 – 415,000 | Raised |
| Aug 3, 2023 | ACO REACH Members | FY2023 | 85,000 – 90,000 | Lowered |
| Aug 3, 2023 | Total Members Live on Platform | FY2023 | 497,000 – 505,000 | Raised |
| Aug 3, 2023 | Total Revenues ($M) | Q3 FY2023 | $1.13B – $1.14B | New |
| Aug 3, 2023 | Total Revenues ($M) | FY2023 | $4.53B – $4.54B | Raised |
| May 9, 2023 | Adjusted EBITDA ($M) | Q2 FY2023 | $2.00M – $10.00M | New |
| May 9, 2023 | Adjusted EBITDA ($M) | FY2023 | -$3.00M – $25.00M | Raised |
| May 9, 2023 | Adjusted EBITDA contribution from ACO REACH | FY2023 | $5.00M – $10.00M | Lowered |
| May 9, 2023 | Geography Entry Costs ($M) | FY2023 | $65.00M – $78.00M | New |
| May 9, 2023 | Medical Margin ($M) | FY2023 | $535.00M – $560.00M | New |
| May 9, 2023 | Medicare Advantage Members | Q2 FY2023 | 403,000 – 405,000 | New |
| May 9, 2023 | ACO REACH Members | Q2 FY2023 | 85,000 – 90,000 | Lowered |
| May 9, 2023 | Total Members Live on Platform | Q2 FY2023 | 488,000 – 495,000 | Raised |
| May 9, 2023 | Avg. Medicare Advantage Members | Q2 FY2023 | 407,000 – 409,000 | Lowered |
| May 9, 2023 | Geography Entry Costs ($M) | Q2 FY2023 | $16.00M – $19.00M | New |
| May 9, 2023 | Medical Margin ($M) | Q2 FY2023 | $138.00M – $148.00M | New |
| May 9, 2023 | Medicare Advantage Members | FY2023 | 405,000 – 410,000 | Lowered |
| May 9, 2023 | ACO REACH Members | FY2023 | 85,000 – 90,000 | Lowered |
| May 9, 2023 | Total Members Live on Platform | FY2023 | 490,000 – 500,000 | Raised |
| May 9, 2023 | Avg. Medicare Advantage Members | FY2023 | 405,000 – 407,000 | Lowered |
| May 9, 2023 | Total Revenues ($M) | FY2023 | $4.41B – $4.44B | Raised |
| May 9, 2023 | Total Revenues ($M) | Q2 FY2023 | $1.11B – $1.12B | New |
| Mar 1, 2023 | Adjusted EBITDA contribution from ACO REACH | FY2023 | $5.00M – $10.00M | Lowered |
| Mar 1, 2023 | Adjusted EBITDA | Q1 FY2023 | $32.00M – $37.00M | New |
| Mar 1, 2023 | Adjusted EBITDA | FY2023 | $75.00M – $90.00M | New |
| Mar 1, 2023 | Medical Margin | FY2023 | $535.00M – $560.00M | New |
| Mar 1, 2023 | Medical Margin | Q1 FY2023 | $160.00M – $170.00M | New |
| Mar 1, 2023 | Medicare Advantage Members | FY2023 | 400,000 – 410,000 | New |
| Mar 1, 2023 | Total Members Live on Platform | FY2023 | 485,000 – 500,000 | Raised |
| Mar 1, 2023 | Medicare Advantage Members | Q1 FY2023 | 385,000 – 390,000 | New |
| Mar 1, 2023 | ACO REACH Members | Q1 FY2023 | 85,000 – 90,000 | Lowered |
| Mar 1, 2023 | Total Members Live on Platform | Q1 FY2023 | 470,000 – 480,000 | Raised |
| Mar 1, 2023 | ACO REACH Members | FY2023 | 85,000 – 90,000 | Lowered |
| Mar 1, 2023 | Total revenues | Q1 FY2023 | $1.07B – $1.09B | New |
| Mar 1, 2023 | Total revenues | FY2023 | $4.28B – $4.37B | New |
| Nov 3, 2022 | Adjusted EBITDA ($M) | FY2022 | $2.00M – $7.00M | Narrowed |
| Nov 3, 2022 | Medicare Advantage Members | FY2022 | 268,000 – 270,000 | Lowered |
| Nov 3, 2022 | Direct Contracting Members | FY2022 | 85,000 – 87,000 | Lowered |
| Nov 3, 2022 | Total Members Live on Platform | FY2022 | 353,000 – 357,000 | Raised |
| Nov 3, 2022 | Medical Margin ($M) | FY2022 | $300.00M – $309.00M | Raised |
| Nov 3, 2022 | Total Revenues ($M) | FY2022 | $2.67B – $2.68B | Raised |
| Aug 4, 2022 | Adjusted EBITDA ($M) | FY2022 | $0 – $10.00M | Reaffirmed |
| Aug 4, 2022 | Adjusted EBITDA ($M) | Q3 FY2022 | -$5.00M – -$2.00M | New |
| Aug 4, 2022 | Direct Contracting Members | Q3 FY2022 | 85,000 – 90,000 | Lowered |
| Aug 4, 2022 | Medicare Advantage Members | Q3 FY2022 | 263,000 – 266,000 | New |
| Aug 4, 2022 | Total Members Live on Platform | Q3 FY2022 | 348,000 – 356,000 | Raised |
| Aug 4, 2022 | Medical Margin ($M) | Q3 FY2022 | $65.00M – $70.00M | New |
| Aug 4, 2022 | Medicare Advantage Members | FY2022 | 265,000 – 270,000 | Lowered |
| Aug 4, 2022 | Total Members Live on Platform | FY2022 | 345,000 – 355,000 | Raised |
| Aug 4, 2022 | Direct Contracting Members | FY2022 | 80,000 – 85,000 | Lowered |
| Aug 4, 2022 | Medical Margin ($M) | FY2022 | $292.00M – $305.00M | New |
| Aug 4, 2022 | Total Revenues ($M) | FY2022 | $2.62B – $2.64B | Raised |
| Aug 4, 2022 | Total Revenues ($M) | Q3 FY2022 | $645.00M – $655.00M | New |
| May 5, 2022 | Adjusted EBITDA ($M) 2 | Q2 FY2022 | $4.00M – $7.00M | New |
| May 5, 2022 | Adjusted EBITDA ($M) 2 | FY2022 | $0 – $10.00M | Reaffirmed |
| May 5, 2022 | Medical Margin ($M) | Q2 FY2022 | $80.00M – $83.00M | New |
| May 5, 2022 | Medical Margin ($M) | FY2022 | $290.00M – $305.00M | Reaffirmed |
| May 5, 2022 | Direct Contracting Members 1 | Q2 FY2022 | 85,000 – 90,000 | Lowered |
| May 5, 2022 | Medicare Advantage Members 1 | Q2 FY2022 | 253,000 – 258,000 | New |
| May 5, 2022 | Total Members Live on Platform 1 | Q2 FY2022 | 338,000 – 348,000 | Raised |
| May 5, 2022 | Medicare Advantage Members 1 | FY2022 | 260,000 – 270,000 | Lowered |
| May 5, 2022 | Direct Contracting Members 1 | FY2022 | 80,000 – 85,000 | Lowered |
| May 5, 2022 | Total Members Live on Platform 1 | FY2022 | 340,000 – 355,000 | Raised |
| May 5, 2022 | Total Revenues ($M) | Q2 FY2022 | $640.00M – $652.00M | New |
| May 5, 2022 | Total Revenues ($M) | FY2022 | $2.51B – $2.59B | New |
| Mar 3, 2022 | Adjusted EBITDA ($M) 2 | Q1 FY2022 | $10.00M – $14.00M | New |
| Mar 3, 2022 | Adjusted EBITDA ($M) 2 | FY2022 | $0 – $10.00M | New |
| Mar 3, 2022 | Medical Margin ($M) | Q1 FY2022 | $82.00M – $88.00M | New |
| Mar 3, 2022 | Medical Margin ($M) | FY2022 | $290.00M – $305.00M | New |
| Mar 3, 2022 | Direct Contracting Members 1 | FY2022 | 80,000 – 85,000 | Lowered |
| Mar 3, 2022 | Medicare Advantage Members 1 | FY2022 | 260,000 – 270,000 | New |
| Mar 3, 2022 | Total Members Live on Platform 1 | FY2022 | 340,000 – 355,000 | Raised |
| Mar 3, 2022 | Medicare Advantage Members 1 | Q1 FY2022 | 245,000 – 250,000 | New |
| Mar 3, 2022 | Direct Contracting Members 1 | Q1 FY2022 | 85,000 – 90,000 | Lowered |
| Mar 3, 2022 | Total Members Live on Platform 1 | Q1 FY2022 | 330,000 – 340,000 | Raised |
| Mar 3, 2022 | Total revenues ($M) | Q1 FY2022 | $635.00M – $650.00M | New |
| Mar 3, 2022 | Total revenues ($M) | FY2022 | $2.51B – $2.59B | New |
| Oct 28, 2021 | Adjusted EBITDA | FY2021 | -$40.00M – -$37.00M | New |
| Oct 28, 2021 | Ending MA Members | FY2021 | 185,000 – 186,000 | New |
| Oct 28, 2021 | Ending DCE Members | FY2021 | 50,000 – 52,000 | Lowered |
| Oct 28, 2021 | Total revenues | FY2021 | $1.82B – $1.83B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases agilon health filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- Update
- News
- Results
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
See a number that looks wrong?